Verona Pharma (United Kingdom)

IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study

Giuseppe Gritti, Federico Raimondi, Diego Ripamonti et al. · 2020 · 170 citations · Full text

Clinical Immunology, Inflammatory Lung Disease, Lung Inflammation +26

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

Lui Franciosi, Zuzana Diamant, Katharine H. Banner et al. · The Lancet Respiratory Medicine · 2013 · 162 citations

Asthma, Medicine, Dual Pde3 +8

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

Antonio Anzueto, Igor Barjaktarević, Thomas M. Siler et al. · American Journal of Respiratory and Critical Care Medicine · 2023 · 119 citations · Full text

Effects of cigarette smoke on Toll-like receptor (TLR) activation of chronic obstructive pulmonary disease (COPD) macrophages

Hannah Metcalfe, Simon Lea, D.A. Hughes et al. · Clinical & Experimental Immunology · 2014 · 81 citations · Full text

Cse Exposure, Lung Inflammation, Innate Immune System +16

The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD

Dave Singh, Katharine Abbott-Banner, Thomas Bengtsson et al. · European Respiratory Journal · 2018 · 60 citations · Full text